Changes are happening - please bear with us while we update our site.

Changes are happening - please bear with us while we update our site. Click here to give us your advice and feedback.

Wesfarmers (ASX:WES) locks target on Australian Pharmaceutical (ASX:API)

Australian Pharmaceutical Industries Ltd (ASX: API) is set to be taken over Wesfarmers Ltd (ASX: WES) after a Scheme of Implementation was signed.

The Australian Pharmaceutical Industries Ltd (ASX: API) share price has moved higher today after the pharmacy distributor entered into a Scheme of Implementation Deed with Wesfarmers Ltd (ASX: WES).

The API share price is up 2.69% to $1.52. Meanwhile, the Wesfarmers share price is down 0.48% to $60.04

A Scheme of Implementation Deed, or SID, is an agreement by the bidder and target that sets out key conditions for the bidder to acquire all of the target’s shares.

The $1.55 cash per share offer values API at $763.6 million and has been unanimously recommended by the API board.

What are the details of the SID?

The entry of the SID is the result of Wesfarmers completing due diligence announced on September 16.

Subsequently, Wesfarmers bought a 19.3% stake in API to fend off a rival bid from Sigma Healthcare Ltd (ASX: SIG).

Current API shareholders will be eligible to receive $1.55 per share minus any fully franked dividends up to a maximum value of 5 cents per share.

API has already declared a final dividend of 2 cents per share. Therefore at this stage, shareholders would receive the 2 cents per share dividend and $1.53 per share from Wesfarmers.

Commenting on the deal, Wesfarmers Managing Director Rob Scott said:

“Wesfarmers continues to see opportunities to invest in and strengthen the competitive position of API and its community pharmacy partners by expanding ranges, improving supply chain capabilities and enhancing the online experience for customers.”

What next for API shareholders?

A Scheme meeting of API shareholders is expected in the first three months of 2022.

However, the offer remains subject to shareholder, court and regulatory approvals.

Each API director intends to vote in favour of the deal in the absence of a superior offer and an independent expert concluding the Scheme in the best interests of shareholders.

Wesfarmers outwits Sigma

Sigma’s last-minute $1.57 per share bid was a two-cent per share premium to Wesfarmers.

However with Wesfarmers being the largest shareholder, in addition to its all-cash offer, Sigma’s small chance of winning has been eliminated.

As a result, the API board has recommended the Wesfarmers offer. It looks like the deal is largely complete and API will be consolidated into Wesfarmers next year.

To keep up to date on all the latest news regarding API, Wesfarmers and the ASX, be sure to bookmark the Rask Media home page.

$50,000 per year in passive income from shares? Yes, please!

With interest rates UP, now could be one of the best times to start earning passive income from a portfolio. Imagine earning 4%, 5% — or more — in dividend passive income from the best shares, LICs, or ETFs… it’s like magic.

So how do the best investors do it?

Chief Investment Officer Owen Rask has just released his brand new passive income report. Owen has outlined 10 of his favourite ETFs and shares to watch, his rules for passive income investing, why he would buy ETFs before LICs and more.

You can INSTANTLY access Owen’s report for FREE by CLICKING HERE NOW and creating a 100% FREE Rask Account.

(Psst. By creating a free Rask account, you’ll also get access to 15+ online courses, 1,000+ podcasts, invites to events, a weekly value investing newsletter and more!)

Unsubscribe anytime. Read our TermsFinancial Services GuidePrivacy Policy. We’ll never sell your email address. Our company is Australian owned.

Information warning: The information on this website is published by The Rask Group Pty Ltd (ABN: 36 622 810 995) is limited to factual information or (at most) general financial advice only. That means, the information and advice does not take into account your objectives, financial situation or needs. It is not specific to you, your needs, goals or objectives. Because of that, you should consider if the advice is appropriate to you and your needs, before acting on the information. If you don’t know what your needs are, you should consult a trusted and licensed financial adviser who can provide you with personal financial product advice. In addition, you should obtain and read the product disclosure statement (PDS) before making a decision to acquire a financial product. Please read our Terms and Conditions and Financial Services Guide before using this website. The Rask Group Pty Ltd is a Corporate Authorised Representative (#1280930) of AFSL #383169.

At the time of publishing, Lachlan does not have a financial or commercial interest in any of the companies or funds mentioned.
Skip to content